Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Idebenone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,074Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Santhera Concludes Agreement with French Authorities on Raxone Reimbursement
    Santhera Concludes Agreement with French Authorities on Raxone Reimbursement

    08 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/08/2603614/0/en/Santhera-Concludes-Agreement-with-French-Authorities-on-Raxone-Reimbursement-and-Plans-to-Submit-a-Request-for-an-Early-Access-Program-for-Vamorolone.html

    GLOBENEWSWIRE
    08 Feb 2023
    Share Share
    Santhera Announces Positive Phase 4 LEROS Trial Data with Raxone
    Santhera Announces Positive Phase 4 LEROS Trial Data with Raxone

    23 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/23/2251433/0/en/Santhera-Announces-Phase-4-LEROS-Trial-with-Raxone-Met-Primary-Endpoint-in-Patients-with-Leber-s-Hereditary-Optic-Neuropathy.html

    GLOBENEWSWIRE
    23 Jun 2021
    Share Share
    Chiesi's Raxone recommended for use within NHS Wales
    Chiesi's Raxone recommended for use within NHS Wales

    26 Apr 2021

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/chiesis_raxone_recommended_for_use_within_nhs_wales_1368441

    Lucy Parsons PHARMATIMES
    26 Apr 2021
    Share Share
    Idebenone (Raxone®) is recommended for use within NHS Wales for the treatment
    Idebenone (Raxone®) is recommended for use within NHS Wales for the treatment

    22 Apr 2021

    // NHS

    https://awmsg.nhs.wales/medicines-appraisals-and-guidance/medicines-appraisals/idebenone-raxone/

    NHS
    22 Apr 2021
    Share Share
    Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa®
    Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa®

    20 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/20/2036079/0/en/Santhera-Completes-Enrollment-of-Phase-3-SIDEROS-Study-with-Puldysa-Idebenone-in-Duchenne-Muscular-Dystrophy-DMD.html

    GLOBENEWSWIRE
    20 May 2020
    Share Share
    EMA validates Santhera’s Puldysa MAA
    EMA validates Santhera’s Puldysa MAA

    27 Jun 2019

    // Anna Smith PHARMATIMES

    http://www.pharmatimes.com/news/ema_validates_santheras_puldysa_maa_1292425

    Anna Smith PHARMATIMES
    27 Jun 2019
    Share Share